



Ordering Provider (13000076)

Michael Milligan DMD 1404 Eastland Drive Ste#101 Bloomington, IL 61701 309-663-4711

Sample Information

Accession: 30067709 Specimen: Oral Rinse Collected: 08/21/2014 Received: 08/22/2014 10:20 Reported: 08/27/2014 09:52 Printed: 08/27/2014 09:53

Result: POSITIVE - 8 PATHOGENIC BACTERIA REPORTED ABOVE THRESHOLD


Bacterial Risk: HIGH - Very strong evidence of increased risk for attachment loss


Aa Td En Fn Pi Cr Pm C




Gender: Male

= Pathogen Load Threshold* DL = Detection Limit **Result Interpretation:** Periodontal disease is caused by specific, or groups of specific bacteria. Threshold levels represent the concentration above which patients are generally at increased risk for attachment loss. Bacterial levels should be considered collectively and in context with clinical signs and other risk factors.







Pathogen

- Aa Aggregatibacter actinomycetemcomitans
- Treponema denticola
- En Eubacterium nodatum
- Fn Fusobacterium nucleatum/periodonticum
- Prevotella intermedia
- cr Campylobacter rectus

Tf Tannerella forsythia

Ec Eikenella corrodens

- Pm Peptostreptococcus (Micromonas)
- Capnocytophaga species
- (gingavalis,ochracea,sputigena)

Result

High Very strong association with PD: Transmittable, tissue invasive, and pathogenic at relatively low bacterial counts. Associated with aggressive forms of disease.

High Very strong association with PD: invasive in cooperation with other bacteria. Usually seen in combination with other bacteria.

High Strong association with PD: specific role uncertain. Often seen in refractory disease.

High Strong association with PD: adherence properties to several oral pathogens; often seen in refractory disease

Clinical Significance

High Strong association with PD: virulent properties similar to Pg; often seen in refractory disease.

High Moderate association with development of PD: usually found in combination with other suspected pathogens in refractory disease.

High Moderate association with PD: detected in higher numbers at sites of active disease.

High Some association with PD: Frequently found in gingivitis. Often found in association with other periodontal pathogens. May increase temporarily following active therapy.

Low Very strong association with PD: common pathogen associated with refractory periodontitis. Strongly

Low Moderate association with PD: Found more frequently in active sites of disease; often seen in refractory disease.

Not Detected: (Pg) Porphyromonas gingivalis

Additional information is available from OralDNA.com on Interpreting Results

related to increasing pocket depths.

Methodology: Genomic DNA is extracted from the submitted sample and tested for 10 species-specific bacteria and 1 genus of bacteria associated with periodontal disease. The bacteria are tested by polymerase chain reaction (PCR) amplification followed by real-time fluorescence detection. Fluorescence readings are interpreted against standard curve data to obtain bacterial concentrations in the sample. Bacterial loads are reported in log copies per mL of sample (e.g. 10^3 = 1000 bacteria copies per mL of collection). *Modified from: Microbiological goals of periodontal therapy; Periodontology 2000, Vol. 42, 2006, 180-218.

Disclaimer: 1. In the event of severe oral or periodontal infections, it is recommended that the clinician consult with an infectious disease specialist or a periodontist. 2. Sample collection for the MyPerioPath Test should occur prior to various dental rinses, in particular those containing antimicrobials. 3. This test was developed, and its performance characteristics determined by OralDNA Labs pursuant to CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. 4. More than 500 types of microorganisms are known to reside on the oral cavity and pharynx. Consequently, the possibility of cross-reactivity between each of these organisms and those detected in this assay cannot be excluded. 5. This assay cannot differentiate between Aggregatibacter actinomycetecomitans and A. segnis; Tannerella forsythia with the following: Bordetella pertussis, Prevotella loescheii, Capnocytophaga species.



Date Of Birth: Gender: Male


Sample Information

Accession: 30067709 Specimen: Oral Rinse Collected: 08/21/2014 LC




Result: POSITIVE - 8 PATHOGENIC BACTERIA REPORTED ABOVE THRESHOLD

Bacterial Risk: HIGH - Very strong evidence of increased risk for attachment loss







Treatment Considerations

- ☑ Office Periodontal Therapy: Protocols to disrupt biofilm and reduce pathogens.
- Systemic Antibiotic Option to Augment Therapy at Clinician's Discretion:

Clinician to determine if local antimicrobials (e.g. Chlorhexidine) and/or local antibiotics (e.g. Arestin) are sufficient to resolve infection.

Published guidelines suggest (subject to allergy, drug interaction, and other medical considerations) the following as a possible adjunct to treatment based on patient's bacterial profile: Amoxicillin 500 mg tid 8-10 days, depending on the severity of infection (1-3) AND Metronidazole 500 mg bid for 8-10 days, depending on the severity of infection. (16,17)

Note: The prescribing doctor is responsible for patient therapy. Consider the patient's dental and medical history (e.g. pregnancy/nursing, diabetes, immuno-suppression, other patient medications) when evaluating the use of antibiotic medications. Many antibiotics may impact/interact with other medications and may produce adverse side effects. Review the manufacturer warnings for any contraindications, or consult with the patient's physician if there are concerns with the selected antibiotic regimen.

- Home Care: Office recommended procedures to daily disrupt biofilm and reduce pathogens.
- Reassessment: Compare clinical signs and bacterial levels pre- and post-treatment. - A 2nd sample should be collected six to eight weeks post-therapy.

Additional Risk Factors

			Additional	riisk i detors				
Clinical		Diagnostic				Medical		
BOP		Localized		Type V Refractory Periodontitis; ADA Code 4900		Family History of PD		
Inflammation/Swelling Bone Loss		Generalized	Ø	Type IV (>6mm); Advanced Periodontitis; ADA Code 4800		Pregnant/Nursing		
Redness/Discoloration	Ø			Type III (4-6mm); Moderate Periodontitis; ADA Code 4700		Immunosupressed Diabetes		
Halitosis/Malodor				Type II (3-4mm); Mild Periodontitis; ADA Code 4600	V	Cardiovascular Disease		
				Type I (1-3mm); Gingivitis; ADA Code 4500		Current Smoker		
				Good Periodontal Health				

Antibiotic Allergies: None Reported

Additional Clinical Information: Patient's MD recommended gum check since pt diagnosed with Diabetes

Tooth Numbers	2	3	14	15	18	19
Pocket Depths	4mm	4mm	4mm	4mm	4mm	4mm

Additional information is available from MyOralDNA.com on:

Interpreting Results	Office Periodontal Protocols	Patient Home Care Steps
Patient Reassessment	Using OralDNA	The Oral-Systemic Connection

Disclaimer: 1. In the event of severe oral or periodontal infections, it is recommended that the clinician consult with an infectious disease specialist or a periodontist. 2. Sample collection for the MyPerioPath Test should occur prior to various dental rinses, in particular those containing antimicrobials. 3. This test was developed, and its performance characteristics determined by OralDNA Labs pursuant to CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. 4. More than 500 types of microorganisms are known to reside on the oral cavity and pharynx. Consequently, the possibility of cross-reactivity between each of these organisms and those detected in this assay cannot be excluded. 5. This assay cannot differentiate between Aggregatibacter actinomycetecomitans and A. segnis; Tannerella forsythia with the following: Bordetella pertussis, Prevotella loescheii, Capnocytophaga haemolytica and Bergeyella zoohelcum; Capnocytophaga species.